BioCentury | Oct 17, 2020
Finance

Novartis Venture Fund’s move to earlier, riskier bets starting to pay off

...deals at least twice this year, as U.K.-based Enterprise Therapeutics Ltd. also...
BioCentury | Oct 7, 2020
Deals

Roche deal for CF program brings return to Enterprise’s syndicate without full takeout

...is paying £75 million ($97 million) up front to acquire a portfolio of TMEM16A potentiators from Enterprise Therapeutics Ltd....
...transmembrane conductance regulatorENaC - Epithelial sodium channelTMEM16A (AN01) - Anoctamin 1 calcium activated chloride channel Paul Bonanos Enterprise Therapeutics Ltd. Anoctamin...
BioCentury | Feb 15, 2020
Management Tracks

Immunomedics names Itri CMO; plus Hua, GenMark, AAM, Vividion, Sophia Genetics, Enterprise, Encoded, Palleon and more

...treat patients with cancer or hereditary disorders (see “Sofia Raises $77M” ). Respiratory disease company Enterprise Therapeutics Ltd....
...Neal Bibeau as CEO. He was president and CEO of Symphony Health Solutions. BioCentury Staff Millendo Therapeutics Inc. Enterprise Therapeutics Ltd. GenMark...
BioCentury | Apr 13, 2018
Financial News

Enterprise raises £29M series B

...Respiratory company Enterprise Therapeutics Ltd. (Falmer, U.K.) raised £29 million ($40.9 million) on April 12 in a series...
...the company has a third preclinical respiratory program against an undisclosed target. Enterprise Therapeutics Ltd., Falmer, U.K. Paul Bonanos Enterprise Therapeutics Ltd. Anoctamin...
BioCentury | Apr 12, 2018
Financial News

Versant, Novartis Venture lead £29M round for Enterprise

...Respiratory company Enterprise Therapeutics Ltd. (Falmer, U.K.) raised £29 million ($40.9 million) in a series B round led...
...Ford said the company has a third preclinical respiratory program against an undisclosed target. Paul Bonanos Enterprise Therapeutics Ltd. Anoctamin...
BioCentury | Apr 12, 2018
Finance

Enterprise engages

...round. Enterprise raised £8 million in series A funding during 2015 and 2016. Paul Bonanos, Assistant Editor Enterprise Therapeutics Ltd. Anoctamin...
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

...U.K. University of Strathclyde £4.3M ($6.3M) Product targeting cAMP-degrading phosphodiesterase enzymes Renal; Inflammation; Cancer Preclinical Enterprise Therapeutics Ltd....
BioCentury | Nov 11, 2016
Financial News

Enterprise Therapeutics completes venture financing

...round led by existing investors Epidarex Capital and Imperial Innovations Group. Enterprise Therapeutics Ltd. , Falmer, U.K. Alex Himes Enterprise Therapeutics Ltd....
BioCentury | Jun 24, 2016
Company News

Management tracks

...Gerry Thomas COO. Boyd will continue as CFO at Oxford BioDynamics Ltd. (Oxford, U.K.) and Enterprise Therapeutics Ltd....
BioCentury | May 25, 2015
Financial News

Enterprise Therapeutics financial update

...Enterprise Therapeutics Ltd. , Falmer, U.K. Business: Pulmonary, Inflammation Date announced: 2015-05-20 Note: Enterprise Therapeutics raised L2.4...
Items per page:
1 - 10 of 11
BioCentury | Oct 17, 2020
Finance

Novartis Venture Fund’s move to earlier, riskier bets starting to pay off

...deals at least twice this year, as U.K.-based Enterprise Therapeutics Ltd. also...
BioCentury | Oct 7, 2020
Deals

Roche deal for CF program brings return to Enterprise’s syndicate without full takeout

...is paying £75 million ($97 million) up front to acquire a portfolio of TMEM16A potentiators from Enterprise Therapeutics Ltd....
...transmembrane conductance regulatorENaC - Epithelial sodium channelTMEM16A (AN01) - Anoctamin 1 calcium activated chloride channel Paul Bonanos Enterprise Therapeutics Ltd. Anoctamin...
BioCentury | Feb 15, 2020
Management Tracks

Immunomedics names Itri CMO; plus Hua, GenMark, AAM, Vividion, Sophia Genetics, Enterprise, Encoded, Palleon and more

...treat patients with cancer or hereditary disorders (see “Sofia Raises $77M” ). Respiratory disease company Enterprise Therapeutics Ltd....
...Neal Bibeau as CEO. He was president and CEO of Symphony Health Solutions. BioCentury Staff Millendo Therapeutics Inc. Enterprise Therapeutics Ltd. GenMark...
BioCentury | Apr 13, 2018
Financial News

Enterprise raises £29M series B

...Respiratory company Enterprise Therapeutics Ltd. (Falmer, U.K.) raised £29 million ($40.9 million) on April 12 in a series...
...the company has a third preclinical respiratory program against an undisclosed target. Enterprise Therapeutics Ltd., Falmer, U.K. Paul Bonanos Enterprise Therapeutics Ltd. Anoctamin...
BioCentury | Apr 12, 2018
Financial News

Versant, Novartis Venture lead £29M round for Enterprise

...Respiratory company Enterprise Therapeutics Ltd. (Falmer, U.K.) raised £29 million ($40.9 million) in a series B round led...
...Ford said the company has a third preclinical respiratory program against an undisclosed target. Paul Bonanos Enterprise Therapeutics Ltd. Anoctamin...
BioCentury | Apr 12, 2018
Finance

Enterprise engages

...round. Enterprise raised £8 million in series A funding during 2015 and 2016. Paul Bonanos, Assistant Editor Enterprise Therapeutics Ltd. Anoctamin...
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

...U.K. University of Strathclyde £4.3M ($6.3M) Product targeting cAMP-degrading phosphodiesterase enzymes Renal; Inflammation; Cancer Preclinical Enterprise Therapeutics Ltd....
BioCentury | Nov 11, 2016
Financial News

Enterprise Therapeutics completes venture financing

...round led by existing investors Epidarex Capital and Imperial Innovations Group. Enterprise Therapeutics Ltd. , Falmer, U.K. Alex Himes Enterprise Therapeutics Ltd....
BioCentury | Jun 24, 2016
Company News

Management tracks

...Gerry Thomas COO. Boyd will continue as CFO at Oxford BioDynamics Ltd. (Oxford, U.K.) and Enterprise Therapeutics Ltd....
BioCentury | May 25, 2015
Financial News

Enterprise Therapeutics financial update

...Enterprise Therapeutics Ltd. , Falmer, U.K. Business: Pulmonary, Inflammation Date announced: 2015-05-20 Note: Enterprise Therapeutics raised L2.4...
Items per page:
1 - 10 of 11